Articles related to FDA

The FDA’s recent approval of toripalimab, based on the JUPITER-02 and POLARIS-02 clinical trials, marks a significant milestone in the treatment of nasopharyngeal carcinoma. With a median progression-free survival of 11.7 months, toripalimab has shown promising results in improving patient outcomes.

The approval of empagliflozin opens up a new avenue in CKD treatment. With its proven efficacy in reducing the risk of disease progression by 28%, it offers a promising alternative for healthcare professionals dealing with this prevalent condition.

The recent study underscores the readiness of pharmacists to dispense mifepristone following the FDA’s rule change. With basic training, nearly all participants expressed confidence in their ability to dispense this medication, highlighting your adaptability and resourcefulness.

As pharmacists, it’s crucial to note that, although these changes in FDA guidelines may not directly impact your practice, they signify a shift in how biosimilars will be identified moving forward. This could potentially influence how you advise patients about these products.

With the approval of Vabysmo, it’s a new era in the treatment of macular edema following RVO. This therapy has demonstrated comparable vision gains to aflibercept in clinical trials, offering a promising alternative for your patients.

The approval of Combogesic IV, backed by data from two phase 3 studies, signifies a major breakthrough in our ongoing efforts to provide effective and safer alternatives to opioids for postoperative pain management.